Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest Therapeutics (Nasdaq: TPST), a clinical-stage biotechnology company focused on developing targeted and immune-mediated cancer therapeutics, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The company's Compensation Committee granted one employee nonqualified stock options to purchase 60,000 shares of common stock under Tempest's 2023 Inducement Plan.
The stock options have a four-year vesting period, with 25% vesting on the first anniversary of the employee's start date, followed by 1/48th of the total shares vesting monthly thereafter. This vesting schedule is subject to continued employment on each vesting date.
Tempest Therapeutics (Nasdaq: TPST), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di terapie mirate e immunomediate per il cancro, ha annunciato un'indennità ai sensi della Regola di quotazione Nasdaq 5635(c)(4). Il Comitato di Compensazione della società ha concesso a un dipendente opzioni su azioni non qualificate per acquistare 60.000 azioni di azioni ordinarie nell'ambito del Piano di Indennità 2023 di Tempest.
Le opzioni su azioni hanno un periodo di maturazione di quattro anni, con il 25% che matura al primo anniversario della data di inizio del dipendente, seguito da 1/48 delle azioni totali che maturano mensilmente successivamente. Questo piano di maturazione è soggetto a un'occupazione continuativa in ciascuna data di maturazione.
Tempest Therapeutics (Nasdaq: TPST), una empresa de biotecnología en etapa clínica centrada en el desarrollo de terapias contra el cáncer dirigidas y mediadas por el sistema inmunitario, ha anunciado una concesión de incentivo bajo la Regla de Cotización 5635(c)(4) del Nasdaq. El Comité de Compensación de la compañía otorgó a un empleado opciones sobre acciones no calificadas para comprar 60,000 acciones de acciones comunes bajo el Plan de Incentivo 2023 de Tempest.
Las opciones sobre acciones tienen un período de consolidación de cuatro años, con el 25% consolidándose en el primer aniversario de la fecha de inicio del empleado, seguido de 1/48 de las acciones totales que se consolidan mensualmente a partir de entonces. Este calendario de consolidación está sujeto a la continuidad del empleo en cada fecha de consolidación.
템페스트 테라퓨틱스(나스닥: TPST)는 표적 및 면역매개 암 치료제를 개발하는 임상 단계의 생명공학 회사로, 나스닥 상장 규정 5635(c)(4) 아래에서 유인 보조금을 발표했습니다. 회사의 보상 위원회는 한 직원에게 60,000주를 구매할 수 있는 비정기 주식 옵션을 부여했습니다, 템페스트의 2023 유인 계획에 따라.
주식 옵션은 4년의 가속 기간을 가지며, 직원의 시작일 첫 번째 기념일에 25%가 가속되고, 이후 매달 1/48의 주식이 가속됩니다. 이 가속 일정은 각 가속 날짜에 계속 고용되는 것을 전제로 합니다.
Tempest Therapeutics (Nasdaq : TPST), une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies ciblées et immunomédiées contre le cancer, a annoncé une subvention d'incitation dans le cadre de la règle de cotation Nasdaq 5635(c)(4). Le comité de rémunération de la société a accordé à un employé des options d'achat d'actions non qualifiées pour acheter 60 000 actions d'actions ordinaires dans le cadre du Plan d'Incitation 2023 de Tempest.
Les options d'achat d'actions ont une période d'acquisition de quatre ans, avec 25 % qui s'acquièrent au premier anniversaire de la date de début de l'employé, suivi de 1/48 des actions totales qui s'acquièrent mensuellement par la suite. Ce calendrier d'acquisition est soumis à un emploi continu à chaque date d'acquisition.
Tempest Therapeutics (Nasdaq: TPST), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung gezielter und immunkontrollierter Krebstherapien konzentriert, hat einen Anreizspruch gemäß der Nasdaq-Notierungsregel 5635(c)(4) bekannt gegeben. Der Vergütungsausschuss des Unternehmens hat einem Mitarbeiter nichtqualifizierte Aktienoptionen zum Kauf von 60.000 Aktien an Stammaktien im Rahmen des Tempest-Vergütungsplans 2023 gewährt.
Die Aktienoptionen haben eine Vesting-Periode von vier Jahren, wobei 25% am ersten Jahrestag des Eintritts des Mitarbeiters vesten, gefolgt von 1/48 der insgesamt Aktien, die monatlich danach vesten. Dieser Vesting-Zeitplan setzt die Fortsetzung der Anstellung an jedem Vesting-Datum voraus.
- Tempest Therapeutics is attracting and retaining talent through stock option grants
- The company has an established 2023 Inducement Plan for employee compensation
- None.
BRISBANE, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 60,000 shares of its common stock under the Company’s 2023 Inducement Plan.
The stock options will vest over a four-year period, with
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.
Investor & Media Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
1 If approved by the FDA
FAQ
How many shares of Tempest Therapeutics (TPST) stock were granted as options in the recent inducement grant?
What is the vesting schedule for the stock options granted by Tempest Therapeutics (TPST) in August 2023?
Under which Nasdaq rule did Tempest Therapeutics (TPST) make the inducement grant in August 2023?
What type of company is Tempest Therapeutics (TPST)?
